---
schema_version: "secwatch.filing_event.v1"
accession: "0001200375-22-000030"
form_type: "8-K"
ticker: "CDXS"
cik: "0001200375"
company_name: "CODEXIS, INC."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T03:45:25.012415+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Codexis Q2 revenue up 51% to $38.4M; CEO Nicols to retire; Dilly appointed

## Summary
- Product revenue surged 135% YoY to $34.6M, driven by Pfizer PAXLOVID enzyme sales.
- Net loss narrowed to $2.6M ($0.04 per share) from $4.3M a year ago.
- CEO John Nicols retiring for family reasons; Dr. Stephen Dilly to become CEO on Aug 9, 2022.
- Reaffirmed FY2022 guidance: total revenue $135-141M, product revenue $112-118M incl. ~$75M from Pfizer.
- Cash and equivalents $90.1M; expects to fund operations through end of 2024.

## SEC filing metadata
- accession: 0001200375-22-000030
- form_type: 8-K
- ticker: CDXS
- cik: 0001200375
- company_name: CODEXIS, INC.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1200375/000120037522000030/0001200375-22-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1200375/000120037522000030/cdxs-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001200375-22-000030
- JSON: https://secwatch.observer/filing/0001200375-22-000030.json
- Plain text: https://secwatch.observer/filing/0001200375-22-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.